Sarissa Capital Management LP Long-Term Concentrated

Location: Greenwich, CT

CIK: 0001577524 · Show all filings

Period: Q4 2018 (← Previous) (Next →)

Filing Date: Feb 14, 2019

Total Value: $451M (100.0% shares, 0.0% debt)

Holdings (10)

BIIB BIOGEN INC. 30.8%

Value $139M Shares 461,858 Est. Cost $285.21 Unrealized +11.9%

INVA INNOVIVA INC. 19.5%

Value $88.14M Shares 5,051,100 Est. Cost $12.33 Unrealized +31.8%

— ALLERGAN PLC 16.2%

Value $73.05M Shares 546,500 Est. Cost $153.24 Unrealized —

IRWD IRONWOOD PHARMACEUTICALS INC. 14.4%

Value $64.77M Shares 6,252,300 Est. Cost $12.17 Unrealized -5.7%

— MEDICINES CO. 11.8%

Value $53.23M Shares 2,781,000 Est. Cost $26.25 Unrealized —

PBYI PUMA BIOTECHNOLOGY INC. 6.1%

Value $27.33M Shares 1,343,000 Est. Cost $30.01 Unrealized 0.0%

— INTERCEPT PHARMACEUTICALS INC. 1.2%

Value $5.442M Shares 54,000 Est. Cost $60.63 Unrealized —

— SHIRE PLC 0.0%

Value $174K Shares 1,000 Est. Cost $152.21 Unrealized —

ABBV ABBVIE INC. 0.0%

Value $92,000 Shares 1,000 Est. Cost $38.85 Unrealized +66.8%

— MIRATI THERAPEUTICS INC. 0.0%

Value $42,000 Shares 1,000 Est. Cost $42.00 Unrealized —

Ticker	Issuer	Shares	Value	%	Est. Cost	Unrealized	Class	CUSIP
BIIB	BIOGEN INC.	461,858	$139M	30.8%	$285.21	+11.9%	COM	09062X103
INVA	INNOVIVA INC.	5,051,100	$88.14M	19.5%	$12.33	+31.8%	COM	45781M101
—	ALLERGAN PLC	546,500	$73.05M	16.2%	$153.24	—	SHS	G0177J108
IRWD	IRONWOOD PHARMACEUTICALS INC.	6,252,300	$64.77M	14.4%	$12.17	-5.7%	COM CL A	46333X108
—	MEDICINES CO.	2,781,000	$53.23M	11.8%	$26.25	—	COM	584688105
PBYI	PUMA BIOTECHNOLOGY INC.	1,343,000	$27.33M	6.1%	$30.01	0.0%	COM	74587V107
—	INTERCEPT PHARMACEUTICALS INC.	54,000	$5.442M	1.2%	$60.63	—	COM	45845P108
—	SHIRE PLC	1,000	$174K	0.0%	$152.21	—	SPONSORED ADR	82481R106
ABBV	ABBVIE INC.	1,000	$92,000	0.0%	$38.85	+66.8%	COM	00287Y109
—	MIRATI THERAPEUTICS INC.	1,000	$42,000	0.0%	$42.00	—	COM	60468T105